Drug profile · INN
rivastigmine tartrate
RIVASTIGMINE TARTRATE
rivastigmine tartrate (RIVASTIGMINE TARTRATE) is a cholinesterases; ache & bche inhibitor. Route of administration: oral. Current US regulatory status: approved.
Drug details — rivastigmine tartrate
- US status
- approved
- Class
- —
- Route
- ORAL
- Patents
- 0
- Programs
- 6
- Data quality
- 0.84
Quick answer
rivastigmine tartrate (RIVASTIGMINE TARTRATE) is a cholinesterases; ache & bche inhibitor. Route of administration: oral. Current US regulatory status: approved.
Key facts
Mechanism of action
Cholinesterases; ACHE & BCHE inhibitor
Primary target: Cholinesterases; ACHE & BCHE
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
Pipeline programs
Related & competitor drugs
Frequently asked questions
What is rivastigmine tartrate?
rivastigmine tartrate (RIVASTIGMINE TARTRATE) is a cholinesterases; ache & bche inhibitor. Route of administration: oral. Current US regulatory status: approved.
What is the brand name for rivastigmine tartrate?
RIVASTIGMINE TARTRATE is a marketed brand name for rivastigmine tartrate. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of rivastigmine tartrate?
rivastigmine tartrate has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.